Literature DB >> 2995366

Characterization of specific high affinity receptors for human tumor necrosis factor on mouse fibroblasts.

P E Hass, A Hotchkiss, M Mohler, B B Aggarwal.   

Abstract

Mouse L-929 fibroblasts, an established line of cells, are very sensitive to lysis by human lymphotoxin (hTNF-beta). Specific binding of a highly purified preparation of hTNF-beta to these cells was examined. Recombinant DNA-derived hTNF-beta was radiolabeled with [3H]propionyl succinimidate at the lysine residues of the molecule to a specific activity of 200 microCi/nmol of protein. [3H]hTNF-beta was purified by high performance gel permeation chromatography and the major fraction was found to be monomeric by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The labeled hTNF-beta was fully active in causing lysis of L-929 fibroblasts and bound specifically to high affinity binding sites on these cells. Scatchard analysis of the binding data revealed the presence of a single class of high affinity receptors with an apparent Kd of 6.7 X 10(-11) M and a capacity of 3200 binding sites/cell. Unlabeled recombinant DNA-derived hTNF-beta was found to be approximately 5-fold more effective competitive inhibitor of binding than the natural hTNF-beta. The binding of hTNF-beta to these mouse fibroblasts was also correlated with the ultimate cell lysis. Neutralizing polyclonal antibodies to hTNF-beta efficiently inhibited the binding of [3H]hTNF-beta to the cells. We conclude that the specific high affinity binding site is the receptor for hTNF-beta and may be involved in lysis of cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995366

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  How the discovery of TNF-α has advanced gastrointestinal diseases and treatment regimes.

Authors:  Joëlle St-Pierre; Kris Chadee
Journal:  Dig Dis Sci       Date:  2014-04       Impact factor: 3.199

2.  Serum and urine levels of tumour necrosis factor in patients with genitourinary cancer and their relevance to disease status.

Authors:  A Akdaş; L Türkeri; T Akoğlu
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

3.  A high molecular weight component of the human tumor necrosis factor receptor is associated with cytotoxicity.

Authors:  A A Creasey; R Yamamoto; C R Vitt
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

4.  TNF-alpha mediated selection of macrophage-resistant gene-regulatory tumor variants.

Authors:  L Remels; A Neirynck; L Brys; E Vercauteren; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1989 Sep-Oct       Impact factor: 5.150

5.  Human tumor necrosis factor increases the resistance against Listeria infection in mice.

Authors:  K Kato; A Nakane; T Minagawa; N Kasai; K Yamamoto; N Sato; N Tsuruoka
Journal:  Med Microbiol Immunol       Date:  1989       Impact factor: 3.402

6.  Sensitivity to tumour necrosis factor-mediated cytolysis is unrelated to manganous superoxide dismutase messenger RNA levels among transformed mouse fibroblasts.

Authors:  J M Boss; S M Laster; L R Gooding
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

7.  Tumor necrosis factor induces the rapid phosphorylation of the mammalian heat shock protein hsp28.

Authors:  A P Arrigo
Journal:  Mol Cell Biol       Date:  1990-03       Impact factor: 4.272

8.  Autocrine tumor necrosis factor (TNF) and lymphotoxin (LT) alpha differentially modulate cellular sensitivity to TNF/LT-alpha cytotoxicity in L929 cells.

Authors:  E Decoster; S Cornelis; B Vanhaesebroeck; W Fiers
Journal:  J Cell Biol       Date:  1998-12-28       Impact factor: 10.539

Review 9.  Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses.

Authors:  B Sherry; A Cerami
Journal:  J Cell Biol       Date:  1988-10       Impact factor: 10.539

10.  Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor.

Authors:  B Y Rubin; S L Anderson; S A Sullivan; B D Williamson; E A Carswell; L J Old
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.